T2DM Flashcards
define
this is hyperinsulinaemia with insulin resistance
progressive disease, if you live long enough you will end up on insulin
describe the process of diagnosis of exclusion for T2DM
- first consider T1DM as this is serious and requires insulin for life
- then consider whether it is something unusual e.g. MODY
cause
genetic and environment (obesity and adiposity lead to increased free fatty acids and adipokines that circulate causing insulin resistance and excessive deposition of fat in liver and muscle which cause genetically vulnerable beta cells to produce excessive insulin)
three presentation settings
- with symptoms e.g. thirst, polyuria, blurred vision, recurrent UTIs, malaise
- screening e.g. obese/overweight or those with FH/high risk ethnicity
- concurrent illness e.g. glucose measured in workup for heart disease
presentation
- slow onset (prediabetes) but can present with DKA/HHS
- middle-aged/elderly (can be young in obese children/high-risk ethnicity is non-Caucasian)
- obese (can be non-obese in elderly)
- FH
diagnosis
- random blood glucose, fasting glucose (2/3 samples must be positive)
- high risk groups should be screened e.g. past history of GDM and those with PCOS
aims of management
manage symptoms
prevent complications
screen for these while preventable
why should patients lower blood sugar despite feeling fine with a high blood sugar?
important to reduce risk of complications
how can blood glucose control be assessed?
HbA1c with target of 48-53mmol/L (doesn’t need to be as low as possible as this can increase risk of cardiovascular complications)
management
lifestyle changes (3 month trial) e.g. diet and exercise pharmacology pathway: - metformin - SUs or TZDs or DPP4i or SGLT2i - insulin or GLP-RA for high BP use ACEI/ARB or SGLT2i
in primary care when should admission to hospital be done?
newly diagnosed T1DM low/normal BMI pregnancy pre-existing chronic renal impairment under 40 specific concern
pharmacological therapies that are harmful for CV
rosigilitazone
pharmacological therapies that are neutral to CV
lixisenatide
DPP4i
SUs
pharmacological therapies that are probably beneficial for CV
exenatide and metformin
pharmacological therapies that are beneficial for CV disease
empagliflozin (and other SGLT2i)
liraglutide
semaglutide
pioglitzone